WO2016118040A8 - A gel containing nifedipine and lidocaine hydrochloride, use of same and a method for preparing same using nanotechnology - Google Patents
A gel containing nifedipine and lidocaine hydrochloride, use of same and a method for preparing same using nanotechnology Download PDFInfo
- Publication number
- WO2016118040A8 WO2016118040A8 PCT/RU2015/000034 RU2015000034W WO2016118040A8 WO 2016118040 A8 WO2016118040 A8 WO 2016118040A8 RU 2015000034 W RU2015000034 W RU 2015000034W WO 2016118040 A8 WO2016118040 A8 WO 2016118040A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gels
- lidocaine hydrochloride
- properties
- gel
- nanotechnology
- Prior art date
Links
- 229960004393 lidocaine hydrochloride Drugs 0.000 title abstract 4
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 title abstract 4
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 title abstract 4
- 229960001597 nifedipine Drugs 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 239000000499 gel Substances 0.000 abstract 8
- 206010002153 Anal fissure Diseases 0.000 abstract 2
- 208000016583 Anus disease Diseases 0.000 abstract 2
- 208000009531 Fissure in Ano Diseases 0.000 abstract 2
- 208000014617 hemorrhoid Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 238000004321 preservation Methods 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000008030 elimination Effects 0.000 abstract 1
- 238000003379 elimination reaction Methods 0.000 abstract 1
- 238000009533 lab test Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000035807 sensation Effects 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The inventions relate to the pharmaceutical industry, including pharmaceutical compositions forming the base of gels, and methods for producing gels which are intended mainly for preventing and/or treating anal fissures, haemorrhoids and diseases associated therewith and for reducing sensations of pain after a haemorrhoidectomy. The inventions relate to compositions and preparation methods, and also to the use of gels including nifedipine and lidocaine hydrochloride. The gels are prepared using nanotechnology. The technical result is achieved by producing such a composition of a gel including nifedipine and lidocaine hydrochloride, each variant of which provides for robustness of the gel properties, transparency, and preservation of the stability of the properties for up to 2 years, and the use of which makes it possible to reduce the clinical symptoms of haemorrhoids, up to and including complete elimination of said symptoms, to heal an anal fissure, and to relieve pain syndrome, including after a haemorrhoidectomy. Furthermore, the technical result is achieved by creating such a method for preparing a gel including nifedipine and lidocaine hydrochloride using nanotechnology, which provides for robustness of the gel properties, transparency, and preservation of the stability of the properties for up to 2 years. All the proposed inventions are industrially applicable, and laboratory tests have shown that the presented subject matter is practically implementable and will be extensively used in the pharmaceutical industry.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/RU2015/000034 WO2016118040A1 (en) | 2015-01-21 | 2015-01-21 | A gel containing nifedipine and lidocaine hydrochloride, use of same and a method for preparing same using nanotechnology |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/RU2015/000034 WO2016118040A1 (en) | 2015-01-21 | 2015-01-21 | A gel containing nifedipine and lidocaine hydrochloride, use of same and a method for preparing same using nanotechnology |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2016118040A1 WO2016118040A1 (en) | 2016-07-28 |
| WO2016118040A8 true WO2016118040A8 (en) | 2016-10-06 |
Family
ID=56417452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/RU2015/000034 Ceased WO2016118040A1 (en) | 2015-01-21 | 2015-01-21 | A gel containing nifedipine and lidocaine hydrochloride, use of same and a method for preparing same using nanotechnology |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2016118040A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2684326C1 (en) * | 2017-11-15 | 2019-04-08 | федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) | Method for preparation of nifedipine gel |
| IT201800002413A1 (en) * | 2018-02-05 | 2019-08-05 | Carmine Antropoli | "COMPOSITION BASED ON NIFEDIPINE FOR USE IN THE TREATMENT OF ANAL RADIUS AND PROCTALGIA" |
| BR102018008324A2 (en) | 2018-04-25 | 2019-11-05 | Laboratorios Ferring Ltda | topical pharmaceutical composition and topical pharmaceutical composition manufacturing process |
| CN112423736A (en) | 2018-06-01 | 2021-02-26 | 塔凡塔医疗匈牙利公司 | Topical amlodipine salts for the treatment of anorectal diseases |
| JP7331149B2 (en) * | 2019-02-25 | 2023-08-22 | ノヴァメディカ リミテッド ライアビリティー カンパニー | Gel for rectal and topical administration |
| RU2733080C1 (en) * | 2019-12-13 | 2020-09-29 | Александр Евгеньевич Баранников | Pharmacological composition for treating proctologic diseases (embodiments) |
| EP4312984A4 (en) * | 2021-04-01 | 2025-02-19 | Steel Therapeutics, Inc. | TOPICAL WIPES CONTAINING NIFEDIPIN AND LIDOCAIN |
| CN113679663B (en) * | 2021-10-09 | 2023-09-29 | 海南回元堂药业有限公司 | Cantharidin emulsifiable paste and preparation method thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002064802A (en) * | 2000-08-21 | 2002-02-28 | Sony Corp | Data transmission system, data transmission device and method, and scene description processing device and method |
| US9107815B2 (en) * | 2008-02-22 | 2015-08-18 | Allergan, Inc. | Sustained release poloxamer containing pharmaceutical compositions |
| RU2483721C1 (en) * | 2012-05-17 | 2013-06-10 | Общество с ограниченной ответственностью "Общество лабораторных исследований медицинских препаратов" | Tisolum-based pharmaceutical composition for treatment of anal fissures |
-
2015
- 2015-01-21 WO PCT/RU2015/000034 patent/WO2016118040A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016118040A1 (en) | 2016-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2016118040A8 (en) | A gel containing nifedipine and lidocaine hydrochloride, use of same and a method for preparing same using nanotechnology | |
| EA201892395A1 (en) | DRUG COMPOSITIONS OF LSD1 INHIBITOR | |
| EP4353257A3 (en) | Method for producing rna compositions | |
| WO2018089851A3 (en) | Influenza vaccine | |
| WO2018115527A3 (en) | Mers coronavirus vaccine | |
| HK1247850A1 (en) | Combination of pd-1 antagonist with an egfr inhibitor | |
| HK1251481A1 (en) | Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists | |
| EP4548972A3 (en) | (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors | |
| ZA202105976B (en) | Pharmaceutical dosage form for application to mucous membranes and methods for producing same | |
| EA201791537A1 (en) | PHARMACEUTICAL COMPOSITION ON THE BASIS OF NANOPARTICLES OF DOCETAXEL-ALBUMIN, METHOD FOR ITS PREPARATION AND ITS APPLICATION | |
| EA201490653A1 (en) | DERIVATIVES ESTRA-1,3,5 (10), 16-TETRAEN-3-CARBOXAMIDE, METHOD FOR THEIR PRODUCTION CONTAINING THEIR PHARMACEUTICAL PREPARATIONS | |
| EA201590491A1 (en) | IMMUNOGENIC COMPOSITION | |
| WO2013188268A8 (en) | Topical ophthalmological pharmaceutical composition containing pazopanib | |
| WO2015056094A3 (en) | Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent | |
| RU2019110980A (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING A 15-HEPC AND METHODS FOR TREATING ASTHMA AND LUNG DISEASES WITH THEIR APPLICATION | |
| EP4477265A3 (en) | Methods of treating new-onset plaque type psoriasis using il-17 antagonists | |
| WO2014203275A3 (en) | An improved process for the preparation of apixaban and intermediates thereof | |
| AR091724A1 (en) | TREATMENT OF MULTIPLE SCLEROSIS WITH A COMBINATION OF LAQUINIMOD AND FAMPRIDINE, PHARMACEUTICAL COMPOSITION | |
| PH12015501377A1 (en) | Solid unit with high fexofenadine content and process for the preparation thereof | |
| TN2015000280A1 (en) | Topical Ophthalmological Pharmaceutical Composition containing Regorafenib | |
| CO7131356A2 (en) | Method for producing anamorelin hydrochloride that has controlled chloride content | |
| EA201391742A1 (en) | PHARMACEUTICAL COMPOSITION INCLUDING FEXOPHENADINE | |
| WO2013188279A8 (en) | Topical ophthalmological pharmaceutical composition containing cediranib | |
| EA201891805A1 (en) | METHOD | |
| JP2017517574A5 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15879121 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 15879121 Country of ref document: EP Kind code of ref document: A1 |